SlatopolskyE., WeertsC., ThielanJ., HorstR., HarterH., MartinK.J.Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest1984; 74: 2136–43.
2.
ZoccaliC., ParlongoS., SicusoC., MessineoL., FinocchiaroP.The influence of 1,25 vit D3 on plasma ANF concentration in haemodialysis patients. Nephrol Dial Transplant1994.
3.
AndressD.L., NorrisK.C., CoburnJ.W.Intravenous calcitriol in treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med1989; 321: 274–9.
4.
KwanJ.T.C., AlmondM.K., BeerJ.C., NoonanK., EvansS.J.W., CunnighamJ.Pulse oral calcitriol in uremic patients: Rapid modification of parathyroid response to calcium. Nephrol Dial Transplant1992; 7: 829–34.
5.
FaugererM.C., FriedlerR.M., MallucheH.H.Efficacy and limitations of pulse i.v. and pulse oral 1,25 vit D3 therapy on bone disease in patients on chronic dialysis. J Am Soc Nephrol1993; 4: 695.
